Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedAug 17, 2025
DataAggregated Company Financials
Companies5
  • 7D7.9%
  • 3M10.4%
  • 1Y-32.2%
  • YTD-15.1%

Over the last 7 days, the Biotech industry has risen 7.9%, driven by gains from Genmab of 8.4%. However, the industry is down 32% over the past year. In the next few years, earnings are forecast to decline by 9.3% annually.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 18 Aug 2025DKK 137.3bDKK 38.6bDKK 16.7b10.5x8.2x3.6x
Wed, 16 Jul 2025DKK 124.6bDKK 27.1bDKK 7.4b11x16.9x4.6x
Fri, 13 Jun 2025DKK 140.2bDKK 27.1bDKK 7.4b11.7x19x5.2x
Sun, 11 May 2025DKK 125.9bDKK 28.0bDKK 7.9b10.1x15.9x4.5x
Tue, 08 Apr 2025DKK 118.9bDKK 27.3bDKK 7.7b10.5x15.5x4.3x
Thu, 06 Mar 2025DKK 158.1bDKK 27.7bDKK 7.8b12.5x20.2x5.7x
Sat, 01 Feb 2025DKK 158.5bDKK 26.0bDKK 4.7b16.5x33.8x6.1x
Mon, 30 Dec 2024DKK 163.5bDKK 26.0bDKK 4.7b17x34.8x6.3x
Wed, 27 Nov 2024DKK 159.3bDKK 26.0bDKK 4.7b16.5x33.9x6.1x
Fri, 25 Oct 2024DKK 178.4bDKK 25.5bDKK 5.5b21.5x32.6x7x
Sun, 22 Sep 2024DKK 191.9bDKK 25.5bDKK 5.5b23.3x35.1x7.5x
Tue, 20 Aug 2024DKK 204.7bDKK 26.1bDKK 5.7b21.4x35.7x7.9x
Thu, 18 Jul 2024DKK 191.6bDKK 24.8bDKK 5.6b17.7x34x7.7x
Sat, 15 Jun 2024DKK 172.3bDKK 24.8bDKK 5.6b17.2x30.6x6.9x
Mon, 13 May 2024DKK 183.7bDKK 24.8bDKK 5.7b18.3x32.4x7.4x
Wed, 10 Apr 2024DKK 184.3bDKK 23.9bDKK 5.0b19.3x36.6x7.7x
Fri, 08 Mar 2024DKK 190.2bDKK 23.9bDKK 5.0b19.4x37.8x8x
Sun, 04 Feb 2024DKK 166.2bDKK 23.3bDKK 4.2b22.8x39.9x7.1x
Tue, 02 Jan 2024DKK 177.2bDKK 23.3bDKK 4.2b25.9x42.6x7.6x
Thu, 30 Nov 2023DKK 172.8bDKK 23.3bDKK 4.2b25.2x41.5x7.4x
Sat, 28 Oct 2023DKK 158.4bDKK 22.0bDKK 4.7b18.5x33.4x7.2x
Mon, 25 Sep 2023DKK 196.1bDKK 22.0bDKK 4.7b23x41.4x8.9x
Wed, 23 Aug 2023DKK 194.1bDKK 20.6bDKK 3.9b36.7x49.2x9.4x
Fri, 21 Jul 2023DKK 210.0bDKK 19.5bDKK 4.4b41.5x47.7x10.7x
Sun, 18 Jun 2023DKK 208.1bDKK 19.5bDKK 4.4b44x47.2x10.6x
Tue, 16 May 2023DKK 220.1bDKK 17.9bDKK 4.0b34x55.1x12.3x
Thu, 13 Apr 2023DKK 201.4bDKK 17.9bDKK 3.5b31.4x56.9x11.2x
Sat, 11 Mar 2023DKK 189.1bDKK 17.9bDKK 3.5b29.2x53.3x10.6x
Mon, 06 Feb 2023DKK 201.8bDKK 14.7bDKK 3.3b30.8x61.7x13.7x
Wed, 04 Jan 2023DKK 226.8bDKK 14.7bDKK 3.3b35.3x69.3x15.4x
Fri, 02 Dec 2022DKK 243.4bDKK 14.7bDKK 3.3b38x74.4x16.5x
Sun, 30 Oct 2022DKK 216.8bDKK 12.4bDKK 1.5b47.8x142.7x17.5x
Tue, 27 Sep 2022DKK 182.5bDKK 12.4bDKK 1.5b40.4x122.6x14.7x
Thu, 25 Aug 2022DKK 211.1bDKK 12.2bDKK 1.6b44.9x134x17.2x
Price to Earnings Ratio

134x


Total Market Cap: DKK 211.1bTotal Earnings: DKK 1.6bTotal Revenue: DKK 12.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 46.1x202320242025
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 8.2x which is lower than its 3-year average PE of 46.3x.
  • The 3-year average PS ratio of 9.0x is higher than the industry's current PS ratio of 3.6x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 120% per year over the last three years.
  • Revenues for these companies have grown 47% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market-0.75%
Healthcare1.42%
Biotech7.89%
Biotech7.89%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GMAB GenmabDKK 1.50k8.4%
+DKK 7.1b		-18.1%PE10.5x
ZEAL Zealand PharmaDKK 370.9012.7%
+DKK 2.8b		-61.0%PE3.9x
BIOPOR BioPortoDKK 1.300.2%
+DKK 909.3k		-41.6%PS16.5x

Latest News

ZEAL
DKK 370.90
Zealand Pharma
7D
12.7%
1Y
-61.0%
author-image

Clinical Catalysts And Roche Alliance Will Advance Obesity Amid Risks

Key Takeaways Major data from obesity drug trials and new industry alliances position the company for expanded future revenues, lowered commercialization risks, and greater global market access. Strong financial reserves enable self-funded innovation and product launches, with pipeline diversification aligning well with emerging trends in obesity treatment.
BIOPOR
DKK 1.30
BioPorto
7D
0.2%
1Y
-41.6%
GMAB
DKK 1,497.50
Genmab
7D
8.4%
1Y
-18.1%
BAVA
DKK 237.50
Bavarian Nordic
7D
-0.04%
1Y
-16.2%
STRAP
DKK 1,080.00
Strategic Partners
7D
-0.9%
1Y
28.0%